SIGHT-DIAGNOSTICS
18.3.2020 14:02:06 CET | Business Wire | Press release
Sight and Sheba Tel Hashomer today announced their new collaboration aimed at mitigating the risk of contamination by COVID-19. Sight’s OLO blood analyser will provide rapid FBC (full blood count) results in a dedicated lab within Israel’s flagship government-run hospital, to process samples of infected patients who are being monitored and treated in a separate field hospital.
Prior to deploying OLO for coronavirus patient testing, Sight ran a two-month evaluation at the central lab of Sheba Tel Hashomer, one of the top 10 hospitals in the world, according to Newsweek, and one of the biggest in Israel. The successful results led to implementing OLO for FBC testing.
Currently, OLO is being used for routine testing of Sheba’s positive coronavirus patients. “OLO’s compact design makes it easy to set up quickly in a setting reserved for testing only contagious blood samples. Eliminating the risks of processing these samples alongside regular lab samples is uniquely advantageous in managing outbreaks of highly infectious diseases,” said Dr. Ram Doolman, Director of Sheba’s Laboratories Division and Automated Mega-Laboratory. “By setting up a quarantined lab that requires special protocols in handling samples from infected patients, we are taking the necessary steps to protect our staff who are on the frontlines, fighting the coronavirus epidemic.”
“Typically, monitoring a patient infected with a virus like COVID-19 would involve taking a blood sample from the infected individual with a needle, labeling vials of drawn blood, sending those vials to a lab outside of the quarantine zone, and receiving the results of the test an hour or more later,” said Yossi Pollak, CEO of Sight. “OLO gives health care providers the ability to use a self-contained cartridge to collect two drops of blood, from either a venous or finger prick sample, insert the cartridge into OLO, and receive FBC results in minutes. For health facilities in countries where OLO is available for point-of-care use, that tactical advantage could make a big difference in a field setting.”
OLO’s technology combines computer vision and AI to digitise each blood sample into more than 1,000 high resolution images. ”We are planning to further develop our technology to diagnose serious conditions, including complications that stem from a viral infection, that have a distinct visual signature in the blood sample,” said Yochay Eshel, VP of R&D at Sight. “We believe in the impact our technology could have on the management of infectious disease, and we are keen to do our part to help.”
Sight is committed to providing rapid and accurate blood tests to aid health professionals in diagnosing and treating patients around the world. By applying technological innovation to blood diagnostics, Sight hopes to improve the ways in which healthcare professionals tackle the challenging effects of infectious diseases.
CAUTIONARY STATEMENT: This press release is intended for distribution outside of the United States. OLO has the CE Mark registration from the European directive for performing FBC tests in point of care settings. In the United States, OLO is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point of care use.
About Sight Diagnostics
Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyser, OLO, performs a Full Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, Parasight, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at sightdx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global styrker sine globale mobilitetskompetencer med samarbejdspartneren Graebel22.5.2026 00:05:00 CEST | Pressemeddelelse
Andersen Global fortsætter med at styrke sin multidimensionelle platform gennem en samarbejdsaftale med Graebel, en global leder inden for medarbejdermobilitet og managed services med hovedkvarter i USA og globale aktiviteter på tværs af Nord- og Sydamerika, Europa og Asien. Graebel blev stiftet i 1950 og samarbejder med mange af verdens mest anerkendte organisationer om en mere simpel tilgang til mobilitet og talentstyring. Virksomheden hjælper organisationer med at støtte medarbejdere gennem hele ansættelsen – fra praktikophold og onboarding til national og international mobilitet samt karriereskift – gennem tjenester, der spænder over strategisk planlægning, hjælp til afrejse og på destinationen, assistance under udstationering, hjemsendelse og design af mobilitetsprogrammer. Gennem strategisk rådgivning og intelligent teknologi gør Graebel det muligt for organisationer at træffe mere informerede beslutninger og afstemme talentmobilitet med en bredere forretnings- og arbejdsstyrkest
The Estée Lauder Companies & Puig End Discussions Regarding a Potential Business Combination21.5.2026 22:05:00 CEST | Press release
The Estée Lauder Companies Reiterates Confidence in Its Beauty Reimagined Strategic Vision On March 23, 2026, The Estée Lauder Companies Inc. (NYSE: EL) and Puig confirmed they were in discussions regarding a potential business combination, but unless and until an agreement was signed between the companies, there could be no assurances regarding the deal or its terms. The Estée Lauder Companies and Puig today announced that the parties have terminated discussions regarding a potential business combination. The Estée Lauder Companies remains fully focused on continuing to execute its Beauty Reimagined strategy, which is well underway and delivering positive results. “We are grateful for the conversations we have had with Puig,” said Stéphane de La Faverie, President and Chief Executive Officer of The Estée Lauder Companies. “Today, we are reiterating our confidence in the power of our incredible brands, our talented teams, and our strength as a standalone company. We are more optimistic
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom